Corcept Therapeutics Incorporated
IT ˙ BIT ˙ US2183521028
62,12 € ↑0,86 (1,40%)
2026-06-03
AKTIENPREIS
SecurityIT:1CORT / Corcept Therapeutics Incorporated
InstitutionMan Group plc
Latest Disclosed Ownership77,604 shares
Latest Disclosed Value $ 3,128,217
Man Group plc reports 14.45% decrease in ownership of 1CORT / Corcept Therapeutics Incorporated

On May 15, 2026 - Man Group plc filed a 13F-HR form disclosing ownership of 77,604 shares of Corcept Therapeutics Incorporated (IT:1CORT) valued at $2,626,119 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 90,708 shares of Corcept Therapeutics Incorporated. This represents a change in shares of -14.45% during the quarter. The current value of the position is $4,820,760 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CORCEPT THERAPEUTICS COM 218352102 77,604 -13,104 -14.45 3,128 -0.89 0.0035
2026-02-17 2025-12-31 13F CORCEPT THERAPEUTICS COM 218352102 90,708 -81,889 -47.45 3,157 -78.00 0.0054
2025-11-14 2025-09-30 13F CORCEPT THERAPEUTICS COM 218352102 172,597 -237,542 -57.92 14,345 -52.35 0.0249
2025-08-14 2025-06-30 13F CORCEPT THERAPEUTICS COM 218352102 410,139 -219,036 -34.81 30,104 -58.11 0.0573
2025-05-15 2025-03-31 13F CORCEPT THERAPEUTICS COM 218352102 629,175 341,295 118.55 71,864 395.41 0.1822
2025-02-14 2024-12-31 13F CORCEPT THERAPEUTICS COM 218352102 287,880 -62,653 -17.87 14,506 -10.58 0.0382
2024-11-14 2024-09-30 13F CORCEPT THERAPEUTICS COM 218352102 350,533 -479,410 -57.76 16,223 -39.84 0.0422
2024-08-14 2024-06-30 13F CORCEPT THERAPEUTICS COM 218352102 829,943 -668,977 -44.63 26,965 -28.59 0.0681
2024-05-15 2024-03-31 13F CORCEPT THERAPEUTICS COM 218352102 1,498,920 672,819 81.45 37,758 40.72 0.0952
2024-02-14 2023-12-31 13F CORCEPT THERAPEUTICS COM 218352102 826,101 26,832 62.58 0.0747
2023-11-14 2023-09-30 13F CORCEPT THERAPEUTICS COM 218352102 16,503 20.42 0.0511
2023-08-14 2023-06-30 13F CORCEPT THERAPEUTICS COM 218352102 615,925 13,704 -4.13 0.0423
2023-05-15 2023-03-31 13F CORCEPT THERAPEUTICS COM 218352102 14,295 2.69 0.0508
2023-02-14 2022-12-31 13F CORCEPT THERAPEUTICS COM 218352102 685,386 -63,015 -8.42 13,920 -27.46 0.0499
2022-11-14 2022-09-30 13F CORCEPT THERAPEUTICS COM 218352102 748,401 19,189 -27.00 0.0891
2022-08-15 2022-06-30 13F CORCEPT THERAPEUTICS COM 218352102 26,287 161.87 0.1114
2022-05-16 2022-03-31 13F CORCEPT THERAPEUTICS COM 218352102 445,740 -4,674 -1.04 10,038 12.56 0.0349
2022-02-14 2021-12-31 13F CORCEPT THERAPEUTICS COM 218352102 450,414 42,549 10.43 8,918 11.10 0.0287
2021-11-15 2021-09-30 13F CORCEPT THERAPEUTICS COM 218352102 407,865 34,818 9.33 8,027 -2.19 0.0282
2021-08-16 2021-06-30 13F CORCEPT THERAPEUTICS COM 218352102 373,047 84,292 29.19 8,207 19.46 0.0289
2021-05-17 2021-03-31 13F CORCEPT THERAPEUTICS COM 218352102 288,755 -37,575 -11.51 6,870 -19.53 0.0302
2021-02-16 2020-12-31 13F CORCEPT THERAPEUTICS COM 218352102 326,330 -449,798 -57.95 8,537 -36.81 0.0375
2020-11-16 2020-09-30 13F CORCEPT THERAPEUTICS COM 218352102 776,128 285,174 58.09 13,509 63.59 0.0532
2020-08-14 2020-06-30 13F CORCEPT THERAPEUTICS COM 218352102 490,954 -260,753 -34.69 8,258 -7.61 0.0416
2020-05-15 2020-03-31 13F CORCEPT THERAPEUTICS COM 218352102 751,707 155,912 26.17 8,938 23.98 0.0579
2020-02-18 2019-12-31 13F CORCEPT THERAPEUTICS COM 218352102 595,795 375,033 169.88 7,209 131.06 0.0237
2019-11-14 2019-09-30 13F CORCEPT THERAPEUTICS COM 218352102 220,762 44,308 25.11 3,120 58.54 0.0116
2019-08-14 2019-06-30 13F CORCEPT THERAPEUTICS COM 218352102 176,454 -261,363 -59.70 1,968 -61.71 0.0071
2019-05-15 2019-03-31 13F CORCEPT THERAPEUTICS COM 218352102 437,817 146,048 50.06 5,140 31.86 0.0195
2019-02-14 2018-12-31 13F CORCEPT THERAPEUTICS COM 218352102 291,769 -178,623 -37.97 3,898 -40.89 0.0173
2018-11-14 2018-09-30 13F CORCEPT THERAPEUTICS COM 218352102 470,392 335,409 248.48 6,595 210.79 0.0241
2018-08-14 2018-06-30 13F CORCEPT THERAPEUTICS COM 218352102 134,983 -54,650 -28.82 2,122 -31.99 0.0087
2018-05-15 2018-03-31 13F CORCEPT THERAPEUTICS COM 218352102 189,633 189,633 3,120 0.0143
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.